Description
Cardiovascular disease and cancer are the leading causes of death in the industrialised world. Anti-cancer therapies have dramatically improved over recent years with increased patient survival rates following diagnosis. Kinase inhibitors in particular have had a major impact on cancer patient survival. However, a number of these agents have been reported to cause serious adverse effects on cardiac function, leading to increased numbers of cancer patients with cardiovascular complications that can, in some cases, lead to death. The true extent of the overall risk to cancer patients is unknown and the underlying mechanism(s) responsible for the cardiotoxic effects remain to be fully identified. Strategies to prevent or mitigate cardiotoxicity resulting from cancer treatment are urgently needed to ensure the best cancer care possible. Future management of anti-cancer drug-related cardiotoxicity will rely on improved understanding of the cellular effects of these agents in the heart. This, combined with improved biomarker identification along with cardiac imaging for monitoring purposes, will be crucial in an overarching strategy to design effective targeted cardioprotective agents. This symposium will be a forum to bring together basic scientists, cardiologists and oncologists to present recent findings that will work towards this overall goal. Ultimately collaboration across these disciplines will be essential for promotion of evidence-based research that can relate to clinical practice in the area of anti-cancer cardiotoxicity.The key aims of the symposium will be to inform upon:
(i) Novel mechanisms of anti-cancer induced cardiotoxicity that may include off-target effects
(ii) Intervention strategies that could reduce/reverse cardiotoxic effects
(iii) Novel drug design that can improve on current therapeutics
| Period | 7 Jul 2019 |
|---|---|
| Event type | Conference |
| Location | Aberdeen, United KingdomShow on map |
| Degree of Recognition | National |